ArticleEcancermedicalscience2025
Acute toxicity profile and treatment response of image guided hybrid brachytherapy using Venezia applicators in locally advanced cervical cancer: a single-centre experience in Pakistan.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing brachytherapy in cervical cancer: Initial dosimetric experience and assessment of Tulip hybrid applicator - the Add-On advantage.Journal of contemporary brachytherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and acute toxicity of hybrid brachytherapy using Venezia applicators in patients with locally advanced squamous cell carcinoma of the cervix. Methods: This prospective study involved 41 patients treated with external beam radiotherapy (EBRT) followed by brachytherapy. Patients received EBRT doses of 45-50.4 Gy with or without simultaneous integrated boost and concurrent chemotherapy. Brachytherapy was administered using Venezia applicators, delivering high-risk clinical target volume (HRCTV) doses of 80-90 Gy or >90 Gy. Treatment responses and toxicities were assessed using Response Evaluation Criteria in Solid Tumours Criteria 1.1, Common Terminology Criteria for Adverse Events Version 5.0, respectively. Results: After five visits, 65.9% of patients achieved complete response, 29.3% partial response and 4.9% stable disease. Acute toxicities were primarily Grade 0-1, with no Grade III or IV toxicities observed. Complete responders exhibited higher rates of Grade 0 toxicities across various parameters, including urination frequency and abdominal pain. Middle-class patients showed higher response rates, although this was not statistically significant. 46.3% Human Papillomavirus positive patients converted to negative status after treatment. There was no significant correlation of response rate with disease stage, EBRT dosage or duration of treatment. Discussion: Hybrid brachytherapy using Venezia applicators allowed for high-dose delivery to HRCTV without exceeding organ tolerance limits, resulting in effective local control (LC) and minimal acute toxicities. The study underscores the potential of hybrid brachytherapy in improving outcomes for cervical cancer patients, particularly in low-middle-income countries. Challenges included small sample size and patient follow-up limitations. Conclusion: Hybrid brachytherapy with Venezia applicators is effective and safe for locally advanced cervical cancer, providing high LC with minimal acute toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.